Microdosing Psilocybin for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Microdosing Psilocybin for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Microdosing psilocybin is the practice of regularly taking imperceptible amounts of psilocybin, a hallucinogenic mushroom compound, for better mood, focus, and healthier aging. Users report benefits, but in studies hiding who received the real compound, gains largely disappear, pointing to expectation. Longevity claims rest on limited, unreplicated cell and animal studies at far larger doses. Risks: unknown product strength, poisoning, and serious danger with psychotic or bipolar illness or lithium. (Full Review)

Protocol

Standard mushroom dose
0.1–0.3 g dried Psilocybe cubensis
About 1–3 mg psilocybin at typical potency; perceptible from about 2.5 mg
Fadiman protocol
One dosing day, two days off
Typically for 4–8 weeks, then a 2–4 week break
Time of day
Morning, single dose
Effects begin within 30–60 minutes and fade within 4–6 hours, leaving evening sleep unaffected
Time to effect
Mood
2–4 weeks
Observational reports; blinded trials over similar periods show no separation from placebo
Psychomotor speed
About 30 days
Faster finger-tapping in a non-randomized cohort; unreplicated
Acute effects
30–60 minutes
Subtle effects; fade within 4–6 hours

Benefits

Contraindications
  • Personal history of schizophrenia, other psychotic disorders, or bipolar I disorder, or a first-degree relative with these conditions
  • People taking lithium (absolute contraindication)
  • Known valvular heart disease (moderate or greater regurgitation on echocardiogram) or pulmonary arterial hypertension
  • Uncontrolled hypertension (resting blood pressure ≥160/100 mmHg) or cardiovascular events (heart attack or stroke) within the past 6 months
  • Seizure disorders
  • Pregnancy or breastfeeding
  • Adults under 21
  • Roles with mandated drug testing or safety-critical duties (pilots, commercial drivers, heavy-machinery operators)
    •
Key Interactions
  • MAOIs (monoamine oxidase inhibitors, e.g., phenelzine, tranylcypromine, moclobemide) (avoid)
  • SSRIs and SNRIs (serotonin-raising antidepressants, e.g., escitalopram, sertraline, venlafaxine) (caution)
  • Antipsychotics (e.g., quetiapine, risperidone, olanzapine) (monitor)
  • Seizure-threshold-lowering drugs (e.g., tramadol, bupropion) (caution)
  • CYP2D6 and CYP3A4 inhibitors (e.g., paroxetine, fluoxetine, ketoconazole, clarithromycin) (monitor)
  • Stimulants (e.g., amphetamine, methylphenidate) and OTC (over-the-counter) decongestants (e.g., pseudoephedrine) (caution)
  • OTC serotonergic cough suppressant dextromethorphan (caution)
  • Serotonergic supplements (St. John's wort, 5-HTP, L-tryptophan, SAMe) (caution)
  • Stack additives: niacin and lion's mane (monitor)
  • Caffeine (monitor)
  • Cannabis and alcohol (caution)
    •

Risk & Side Effects

  • High:
  • Medium: Transient physical discomfort, headache, drowsiness & anxiety; poisoning from misidentified or adulterated products
    •
  • Low: Acute impairment of cognitive control; blood pressure & heart rate elevation; psychiatric destabilization; unintended psychedelic effects from dose variability; persistent perceptual changes
    •
  • Speculative: Valvular heart disease; tolerance; cancer risk from delayed senescence
    •

Monitoring

Marker Target Why
Blood pressure 110–120/70–80 mmHg Detect acute rises
Resting heart rate 50–70 bpm Detect stress-response activation
Echocardiogram No valve regurgitation beyond trace Screen valve changes
PHQ-9 0–4 Track depressive symptoms
GAD-7 0–4 Track anxiety
hs-CRP <1.0 mg/L Track systemic inflammation

Cadence: Baseline before the first dose (echocardiogram only with a heart murmur or planned cumulative use beyond 6 months); blood pressure 1–2 hours after each of the first 3 doses; PHQ-9 and GAD-7 at 2 weeks, 4 weeks, and at the end of each cycle; hs-CRP every 6–12 months; echocardiogram every 12 months during extended use

Qualitative Assessment

  • Mood stability and emotional reactivity
  • Anxiety or restlessness on dosing days
  • Sleep quality and sleep onset time
  • Focus and ability to complete demanding tasks
  • Creativity and problem-solving
  • Energy and motivation
  • Headaches or physical discomfort
  • Any perceptual changes, unusual beliefs, or elevated mood (stop signals)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.